Advances in SLE, osteoporosis, and RA highlighted at California Rheumatology Alliance meeting.
Drug Updates
Information on new approvals and medication safety.
ACR Issues Guidelines, Recommendations for Lupus Nephritis, RA
Detailed screening and treatment recommendations based on current evidence, extensive literature review.
Clinical Opportunities at the 2012 ACR/ARHP Annual Meeting
The Annual Meeting will provide numerous opportunities to learn the latest clinical findings in the field and to update their knowledge in all aspects of rheumatology.
Medication Quick Guides Offer Infusion Staff a Streamlined Resource
The ACR/ARHP Medication Quick Guides offer easily accessable pharmaceutical information to rheumatologists.
10 Tips for Better Communication in Rheumatology
Bring clarity to your interactions with patients, staff, and colleagues.
Drug Updates: Citalopram hydrobromide, Statins, and More
Information on new approvals and medication safety
Désirée Van Der Heijde, MD, PhD, a Key Driver of Treatment Advances
Dr. van der Heijde learned early in her career that serendipity often plays a role in clinical research and treatment advances.
American College of Rheumatology (ACR) Advocates for Improved Access to Critical Treatments
The ACR is promoting federal legislation to eliminate high cost sharing for specialty tier medications in all states.
Biosimilar Drugs Face Challenges to Reach the U.S. Market
To date, the FDA has not approved a biosimilar product. In its own discussion of the merits and obstacles to biosimilar drugs, the ACR sponsored a panel session titled, “Biosimilar Products in the U.S. Market: Fact or Fiction?” at the 2011 ACR/ARHP Annual Scientific Meeting here in November.
- « Previous Page
- 1
- …
- 9
- 10
- 11
- 12
- 13
- Next Page »